ReCyte Therapeutics, a BioTime Subsidiary, Announces Peer-Reviewed Publication on Pericyte-Like Progenitor Cells

New isolated cell line has the potential to address a critical unmet medical need for patients suffering from ischemic vascular disease

ALAMEDA, Calif.--()--ReCyte Therapeutics, a subsidiary of BioTime, Inc., a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced the publication of a scientific paper titled, “A novel lineage restricted, pericyte-like cell line isolated from human embryonic stem cells,” by Midori Greenwood-Goodwin, Jiwei Yang, Mohammad Hassanipour, and David Larocca. The article was released in the peer-reviewed online publication in Scientific Reports. The online version of the article can be found at www.nature.com/articles/srep24403.

In the article, researchers at ReCyte Therapeutics demonstrate the successful isolation of a new type of human blood vessel support cell that is involved in the formation and stabilization of blood vessels, a process known as angiogenesis. Unlike typical angiogenic support cells which are multi-talented and can turn into other types of tissues such as bone, these precursor cells, termed PC-M cells, are highly specialized to support and strengthen blood vessels.

“When you want a specific job done, its best to call a specialist for treatment,” said Dr. David Larocca, Vice President of Research and Development. “That’s why we believe these novel pericytes (PCs) may be an ideal source of cells for promoting new blood flow in patients suffering from ischemic vascular disease (IVD) where clogged arteries have blocked blood flow to limbs or the heart.”

Left unchecked, IVD often leads to amputation or heart failure for patients that have failed, or are not candidates for surgical interventions. Thus, there is a critical unmet medical need for new angiogenic therapies. Importantly, PC-M cells are highly stable and have a high capacity to replicate under standard laboratory conditions. They therefore can be manufactured on an industrial scale needed to treat a large patient population. At ReCyte, we are currently investigating the use of PC-M cells for treating critical limb ischemia, a late stage of IVD that afflicts diabetics and the elderly.

We have also developed a PC-M cell based co-culture assay kit called VascuNet™ (sold by Ascendance Biotechnology, Inc.) that’s designed to be used to screen for drugs that affect human blood vessel growth and stability. This novel assay mimics the body’s own angiogenic mechanisms for growing blood vessels which involves both supporting pericytes, and the endothelial cells that line the vessel walls. This biomimetic VascuNet™ assay can be used to discover new anti-angiogenic cancer drugs that kill tumors by cutting off or destabilizing their blood supply. It can also be used to screen for pro-angiogenic drugs that increase blood flow for treating ischemia.

The paper, based off of BioTime/ReCyte’s extensive research and discoveries involving iPS cells, if developed, could potentially bring value to the pharmaceutical industry interested in developing cardiovascular and cancer therapies. This development ties into BioTime’s broader strategy to allow its non-core therapeutic assets to mature into successful regenerative cell therapies, for a wide variety of degenerative diseases, to help address the critical unmet medical needs of patients worldwide.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent stem cell assets. The foundation of our core therapeutic technology platform is pluripotent stem cells that are capable of becoming any of the cell types in the human body. Pluripotent stem cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent stem cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

In order to efficiently advance product candidates through the clinical trial process, we have historically created operating subsidiaries for each program and product line. This approach has fostered efficient use of resources and reduced shareholder dilution as compared to strategies commonly deployed by the biotechnology industry, as the various programs and product lines have advanced through basic research and animal studies. We and our subsidiaries now have four therapeutic product candidates in human clinical trials, each of which addresses a large market opportunity. In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and stem cell research products, and mobile health software applications.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.

Contacts

BioTime, Inc.
Dan L. Lawrence, 510-775-0510
dlawrence@biotimeinc.com
or
EVC Group, Inc.
Michael Polyviou, 646-445-4800
mpolyviou@evcgroup.com
or
Media Contact:
Gotham Communications, LLC
Bill Douglass, 646-504-0890
bill@gothamcomm.com

Contacts

BioTime, Inc.
Dan L. Lawrence, 510-775-0510
dlawrence@biotimeinc.com
or
EVC Group, Inc.
Michael Polyviou, 646-445-4800
mpolyviou@evcgroup.com
or
Media Contact:
Gotham Communications, LLC
Bill Douglass, 646-504-0890
bill@gothamcomm.com